A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07377565 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Nielsen Fernandez-Becker

Collaborators